Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Inclusion Criteria:

• Have Type 2 Diabetes (T2D)

• Have HbA1c ≥ 7.0% to ≤ 9.5%

• Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening

• Are of stable weight for at least 90 days prior to screening

• Have a Body Mass Index (BMI) ≥ 23.0 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

• Have Type 1 Diabetes (T1D)

• Have a history of ketoacidosis or hyperosmolar state or coma within the last 6months prior to screening

• Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6months prior to screening

• Are currently receiving or planning to receive treatment for diabetic retinopathyand/or macular edema

• Have an estimated glomerular filtration rate (eGFR) <15 milliliters/minute/1.73meter squared (mL/min/1.73 m^2) as determined by the central laboratory

• Have a prior or planned surgical treatment for obesity

• Have New York Heart Association Functional Classification IV congestive heartfailure

• Have had an acute myocardial infarction, stroke, or were hospitalized for congestiveheart failure within 90 days prior to screening

• Have a known clinically significant gastric emptying abnormality

• Have a history of an active or untreated malignancy or are in remission from aclinically significant malignancy for less than 5 years

• Have any lifetime history of a suicide attempt

• Had chronic or acute pancreatitis

• Have a family or personal history of medullary thyroid carcinoma or multipleendocrine neoplasia (MEN) syndrome Type 2

• Have taken prescribed or over-the-counter medication, or alternative remedies,intended to promote body weight reduction within 90 days prior to screening.